Metrics for antibody therapeutics development
暂无分享,去创建一个
[1] J. Reichert,et al. Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.
[2] Janice M. Reichert,et al. Monoclonal antibodies in the clinic , 2001, Nature Biotechnology.
[3] Donald L Drakeman,et al. The future of monoclonal antibody technology , 2010, mAbs.
[4] Janice M Reichert,et al. Development trends for therapeutic antibody fragments , 2009, Nature Biotechnology.
[5] R. Owens,et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. , 1994, Cancer research.
[6] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[7] H. de Haard,et al. Properties, production, and applications of camelid single-domain antibody fragments , 2007, Applied Microbiology and Biotechnology.
[8] P. Hudson,et al. Engineered antibodies , 2003, Nature Medicine.
[9] L. Álvarez-Vallina,et al. Antibody engineering: facing new challenges in cancer therapy , 2005, Acta Pharmacologica Sinica.
[10] S. Muyldermans,et al. Single-domain antibodies as building blocks for novel therapeutics. , 2008, Current opinion in pharmacology.
[11] Janice M Reichert,et al. Monoclonal antibodies as innovative therapeutics. , 2008, Current pharmaceutical biotechnology.
[12] F. Veronese,et al. The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.
[13] Joshua P Cohen,et al. New challenges to medicare beneficiary access to mAbs , 2009, mAbs.
[14] Janice M Reichert,et al. Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.